Sinclair conducts pre-clinical large animal research, develops animal models in a variety of species, and produces miniature swine. Through the development of animal models, Sinclair helps the pharmaceutical and biotechnology industry to evaluate their compounds using a relevant animal model and to verity the efficacy of those compounds. Evaluating the efficacy of the compounds in a pre-clinical setting leads to fast, accurate, and economical results. These efficacy studies provide a better knowledge of the compound activity prior to the clinical trials study phase. Previous efficacy studies conducted at Sinclair using large animal models have drastically influenced the course of compound development and saved significant time and investment during the licensing process for the final, more active, compound. The use of relevant large animal models helps sponsors to verify dosages and methods of delivery while providing information on the compound's efficacy. Large animals, such as miniature swine, are more relevant to human physiological processes than rodents and are large enough for frequent sampling as needed during longitudinal studies. Sinclair has developed a number of animal models with high relevance to specific human pathological conditions. These large animal models include, but not limited to,

• Diabetes Type 1 and 2

• Obesity, Weight Loss, Resistance to Weight Gain

• Osteoporosis

• Melanoma (Cancer)

• Dermatological Modeling (white hairless miniature swine for transdermal
drug delivery, wound healing, irritation, and photosensitization)

• Transplantation

• Nutrition

• Surgical Modeling

• Atherosclerosis

Sinclair is very experienced in conducting non-standard study protocols and can provide significant contributions to the design of complex protocols. Sinclair is AAALAC accredited and complies with GLP regulations. We guarantee confidentiality, emphasize open and timely communication with clients, and provide quick response and rapid turn-around times.